Trial Title:
A Study to Evaluate the STI-8591 in Subjects With Advanced Acute Myeloid Leukemia (AML)
NCT ID:
NCT05947344
Condition:
AML, Adult
Conditions: Official terms:
Leukemia, Myeloid, Acute
Conditions: Keywords:
FLT3 inhibitor
Study type:
Interventional
Study phase:
Phase 1
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
STI-8591
Description:
Seven dosing cohorts will be evaluated in the dose escalation phase: 20mg,
40mg,80mg,120mg, 160mg, 200mg, 240mg.Expansion is planned in three dose groups of 120mg,
160mg, and 200mg.
Arm group label:
STI-8591 in Advanced Acute Myeloid Leukemia (AML)
Other name:
STI-8591 alone
Summary:
This is a first-in-human, dose-escalation and dose-expansion Phase I study to evaluate
the safety, tolerability, pharmacokinetics (PK) and efficacy of STI-8591 in subjects with
advanced AML who have signed an informed consent form (ICF) and have been screened for
enrollment in this study.
- Dose escalation phase: rapid titration and conventional 3+3 test design were used to
evaluate the safety, dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and
PK characteristics of STI-8591.
- Dose Expansion Phase: Evaluate the safety, preliminary efficacy and determine the
recommended phase II dose (RP2D) of STI-8591 for the treatment of subjects with
advanced AML under the conditions of reaching the expanded dose.
Detailed description:
Dose escalation phase:Based on the preclinical trial data and with reference to the
modified Fibonacci method, the dose escalation ratios are 100%, 100%, 50% and 6.7%, and
the initial 5 dose groups for STI-8591 dose escalation are 40, 80, 160, 240 and 280
mg/day, respectively. Screened subjects will be entered into the 5 dose groups in order
of succession from lowest to highest dose.This test dose increment will be performed
using the rapid titration method and the traditional 3+3 test design.
Dose expansion phase:During dose escalation, for dose groups (except for ≥2 DLT dose
groups) when the following dose signals suggesting initial efficacy are present.
1) CR, CRh or CRi in ≥1 subject in either dose group.2) Median decrease in FLT3
phosphorylation was ≥90% in ≥3 subjects in either dose group.The SRC will decide
whether to initiate an extension study for that dose group and its subsequent dose
groups at the same time as the dose escalation to the next dose group. Subjects in
the dose escalation phase will be administered BID every 28 days in 1 cycle, with
≥8h between doses, fasting for at least 2 hours before and at least 1 hour after
dosing with approximately 240mL of water (subject to adjustment based on data
results from the dose escalation phase) . If initiation was determined, the dose
group identified for initiation and its subsequent dose group extension studies were
further enrolled in 14 to 17 cases [a total of 20 cases in each dose group, with
FLT3 mutation-positive (FLT3 internal tandem repeat (ITD) and/or FLT3 tyrosine
kinase structural domain (TKD) mutation-positive subjects enrolled in at least 10
cases] to further define the final RP2D.
Criteria for eligibility:
Criteria:
Inclusion Criteria:
To be enrolled in this study, subjects must meet all of the following inclusion criteria.
1. Voluntary signing of ICF.
2. Age ≥ 18 years old.
3. Expected survival >12 weeks.
4. Dose escalation component: Advanced primary AML or myelodysplastic neoplasm (MDS)
secondary to AML or MDS/myeloproliferative neoplasm (MPN)-associated AML (AML-MR)
diagnosed by 2022 WHO AML typing and with diagnostic criteria that have failed
standard therapy or are intolerant of standard therapy may be considered for
inclusion in this component of the study. Dose extension section: Advanced primary
AML or MDS secondary to AML or AML-MR diagnosed according to the 2022 WHO AML typing
and associated diagnostic criteria, who have failed or are intolerant to standard
therapy, or who are unable to access standard therapy for various reasons, may only
be considered for inclusion in this part of the study.
5. ECOG scores physical fitness status 0 to 2.
6. Subjects are willing to undergo a bone marrow aspiration/biopsy as required by the
protocol, which is used to assess the subject's response to treatment.
7. Laboratory test index requirements within 7 days prior to the first dose, including:
White blood cell count (WBC) ≤ 20 x 109 /L [(hydroxyurea is allowed up to the first
dose to stabilize the WBC count up to a maximum dose of 5 g/day. Hydroxyurea may be
continued for up to 28 days after the first dose (i.e., the first dosing cycle) at
the discretion of the investigator, but generally not beyond 28 days)].
Alanine aminotransferase (ALT) ≤ 2.5 x ULN (≤ 5 x ULN if liver involvement is
known).
Aspartate aminotransferase (AST) ≤ 2.5 x ULN (≤ 5 x ULN if liver involvement is
known) Total bilirubin (TBIL) ≤ 1.5 x ULN (< 3.0 x ULN if diagnosed with Gilbert's
syndrome) Estimated glomerular filtration rate (eGFR, calculated according to the
Cockcroft-Gault formula or by measuring 24-hour urine) > 50 mL/min.
8. Residual toxicity of previous antitumor therapy ≤ grade 1 (except alopecia and
hyperpigmentation; see inclusion criteria 7 for laboratory test indices)
9. Be willing and able to comply with the study schedule and all other study protocol
requirements.
10. Women of childbearing potential (WOCBP) (women of childless potential defined as
sexually mature women who have undergone hysterectomy or bilateral oophorectomy or
bilateral salpingo-oophorectomy or bilateral tubal ligation/closure, or who are
unable to have children because of congenital or acquired disease or who have been
spontaneously menopausal for ≥12 months) must have a negative blood pregnancy test
performed during screening.
11. Female subjects of childbearing potential and male subjects whose partners are of
childbearing potential must use a highly effective method of contraception from the
time of screening until 180 days after the last treatment.
12. Subjects are required to provide FLT3 mutation status testing within 6 months prior
to the first dose, and if not, are willing to undergo screening period testing as
required by the protocol.
Exclusion Criteria:
To be enrolled in this study, subjects must not meet any of the following exclusion
criteria.
1. Known hypersensitivity to any component of the study drug formulation.
2. Subjects were diagnosed with acute promyelocytic leukemia (APL).
3. Subjects have BCR-ABL positive leukemia (chronic myelogenous leukemia acute).
4. Subjects developed secondary AML after previous antitumor therapy for other tumors
(except MDS, MDS/MPN).
5. Subjects had CNS leukemia with associated clinical symptoms.
6. Enrolled in any therapeutic clinical study within 28 days prior to the first dose
and enrolled in treatment, except in the survival follow-up phase of the
interventional study.
7. Received anti-tumor therapy (including chemotherapy, immunotherapy, endocrine
therapy, targeted therapy, etc.) within 28 days or 5 half-lives (whichever is
shorter) prior to the first dose. Received radiotherapy within 14 days prior to the
first dose. Palliative radiotherapy for symptom control is allowed to be completed
at least 7 days prior to the first dose. Have received herbal therapy with approved
indications for antitumor use within 7 days prior to the first dose.
8. ≥ Grade 2 graft-versus-host disease (GvHD), including acute, chronic or overlapping
or escalating GvHD therapy within 14 days prior to first dose or being treated with
systemic cortisol hormone for GvHD.
9. Received chimeric antigen receptor T-cell immunotherapy (CAR-T) within 3 months
prior to the first dose.
10. Strong inducer or strong inhibitor of cytochrome P450 (CYP450) 2C8 or 3A4 enzymes
taken within 14 days prior to the first dose, unless the investigator assesses that
the drug is necessary for the subject's treatment regimen.
11. Major surgery within 28 days prior to first dose or minor surgery within 7 days
prior to first dose, except diagnostic biopsy, insertion of vascular access device
12. Subjects have clinically significant coagulation abnormalities, such as disseminated
intravascular coagulation (DIC), hemophilia A, hemophilia B, and vascular
hemophilia.
13. Intractable hypokalemia or hypomagnesemia that is not easily corrected by
symptomatic treatment and with previous recurrent episodes.
14. Active tuberculosis, or interstitial lung disease requiring corticosteroid therapy,
drug-induced interstitial lung disease, history of radiation pneumonia, or
clinically active interstitial lung disease as suggested by any current evidence,
prior to the first dose.
15. Presence of an uncontrolled active infection (defined as exhibiting persistent
signs/symptoms associated with the infection that do not improve despite appropriate
antibiotic or other treatment) within 72 hours prior to the first dose. Ongoing use
of prophylactic antibiotics, antifungals, or antivirals is eligible for enrollment.
16. Inability to take oral medication, history of previous surgery or severe
gastrointestinal disorders such as dysphagia and active gastric ulcer, which the
investigator believes may affect the absorption of the study drug.
17. History of deep vein thrombosis, pulmonary embolism, or any other serious
thromboembolism (other than thrombosis due to vascular access devices or superficial
venous thrombosis) within 3 months prior to the first dose.
18. Active or uncontrolled HBV (HBsAg positive and/or HBcAb positive with positive
HBV-DNA titers), HCV (HCV-Ab positive with positive HCV-RNA titers), HIV positive.
19. History of clinically significant cardiovascular disease, including.
1. Congestive heart failure (NYHA classification ≥ Class III) within 6 months
prior to first dose
2. Unstable angina occurred within 6 months prior to the first dose.
3. Myocardial infarction within 6 months prior to the first dose.
4. Presence of poorly controlled arrhythmias at screening (e.g., subjects with
ventricular tachycardia occurring during antiarrhythmic drug therapy will be
excluded; however, subjects with atrioventricular block of degree I or
asymptomatic left anterior bundle branch block/right bundle branch block do not
have to be excluded).
5. Diagnosis or suspicion of long QT syndrome at screening (including a family
history of long QT syndrome)
6. QTcF interval >450 msec (using the Fridericia formula).
7. Left ventricular ejection fraction (LVEF) <45%.
8. Uncontrolled hypertension (on the basis of lifestyle improvement, blood
pressure has not reached the standard after applying a reasonably tolerable
adequate dose of 2 or more antihypertensive drugs for more than 1 month, or
blood pressure can be effectively controlled only after taking 4 or more
antihypertensive drugs).
9. Stroke, cerebrovascular accident or transient ischemic attack within 6 months
prior to the first dose.
20. Pregnant or lactating women.
21. Any active serious mental illness, medical condition or other symptom/condition
that, in the judgment of the investigator, may interfere with treatment, compliance
or the ability to provide informed consent.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
the First Affiliated Hospital, College of Medicine, Zhejiang University
Address:
City:
Hangzhou
Country:
China
Status:
Recruiting
Contact:
Last name:
Jie Jin, Doctor
Phone:
0571-87236896
Email:
jiej0503@163.com
Start date:
December 8, 2023
Completion date:
July 2025
Lead sponsor:
Agency:
Zhejiang ACEA Pharmaceutical Co. Ltd.
Agency class:
Industry
Source:
Zhejiang ACEA Pharmaceutical Co. Ltd.
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05947344
